Evidence map›Paper›PMID 33935979›Full record

ArticleFrontiers in endocrinology2021

Case Report: Re-Treatment With Lu-DOTATATE in Neuroendocrine Tumors.

Elena María Vida Navas, Alberto Martínez Lorca, Aintzane Sancho Gutiérrez, Lucia Sanz Gómez, Teresa Navarro Martínez, Enrique Grande Pulido, Alfredo Carrato Mena, Pablo Gajate Borau

Open access · goldAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in endocrinology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed, 1 pooled it
0.3field-weighted citation impact, top 42% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 1 synthesis or guideline pooled it, 3 citations in OpenAlex.

  1. Guideline
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 1 country.

Elena María Vida NavasMedical Oncology Department, Hospital Universitario Ramón y Cajal, Instituto Ramón y Cajal de Investigación Sanitaria, Madrid, Spain.
Alberto Martínez LorcaNuclear Medicine Department, Hospital Universitario Ramón y Cajal, Madrid, Spain.
Aintzane Sancho GutiérrezMedical Oncology Department, Hospital Universitario Cruces, Baracaldo, Spain.
Lucia Sanz GómezMedical Oncology Department, Hospital Universitario Ramón y Cajal, Instituto Ramón y Cajal de Investigación Sanitaria, Madrid, Spain.
Teresa Navarro MartínezNuclear Medicine Department, Hospital Universitario Ramón y Cajal, Madrid, Spain.
Enrique Grande PulidoMedical Oncology Department, MD Anderson Cancer Center Madrid, Madrid, Spain.
Alfredo Carrato MenaMedical Oncology Department, Hospital Universitario Ramón y Cajal, Instituto Ramón y Cajal de Investigación Sanitaria, Madrid, Spain.
Pablo Gajate BorauMedical Oncology Department, Hospital Universitario Ramón y Cajal, Instituto Ramón y Cajal de Investigación Sanitaria, Madrid, Spain.
Hospital Universitario Ramón y Cajal · ESInstituto Ramón y Cajal de Investigación Sanitaria · ESHospital de Cruces · ESMD Anderson Cancer Center Madrid · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Peptide receptor radionuclide therapy (PRRT) is an established treatment in advanced neuroendocrine tumors (NETs), which overexpressed somatostatin receptors. However, after progression there are a limited number of available treatments. We want to share a case report about a patient with a NET re-treated with

Indexed as

AdultAntineoplastic AgentsBone NeoplasmsEverolimusHumansMagnetic Resonance ImagingMaleNeuroendocrine TumorsOctreotideOrganometallic CompoundsRadiopharmaceuticalsRectal NeoplasmsRetreatmentSunitinibTomography, X-Ray ComputedAntineoplastic AgentsEverolimuslutetium Lu 177 dotatateOctreotideOrganometallic CompoundsRadiopharmaceuticalsSunitinibcase reportLu-DOTATATEneuroendocrine neoplasmsneuroendocrine tumorspeptide receptor radionuclide therapy

Identifiers

PMID33935979
PMCPMC8082310
OpenAlexW3155502583

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.